The Chief Executive of German biotechnology company IDT Biologika, Juergen Betzing, said the company plans to start a phase II trial of its experimental COVID-19 vaccine by the end of the year, Reuters news agency reported on Monday.
IDT Biologika is a German contract development and manufacturing company focussed on the development and manufacture of live viral vaccines.
Betzing was quoted as saying at a news conference that the company hopes to be able to apply for approval in 2021.
"If all clinical tests are successful, we could apply for an accelerated approval at the end of 2021," Betzing added.
Dr. Reddy's Receives Approval to Conduct Phase 3 Clinical Trial for Sputnik V Vaccine in India
Carbon Health Launches COVID-19 Vaccination Platform to Accelerate National Rollout
Kyruus Enables Online Scheduling for COVID-19 Vaccine Visits
China's Sinopharm says COVID-19 vaccine safe for children and teenagers
Publix and the State of Florida to Bring COVID-19 Vaccinations to Three Florida Counties
OnSolve's CodeRed used across the US for the management of information related to COVID-19 vaccine
Meijer Pharmacies to administer COVID-19 vaccines in the State of Michigan
China's CanSino Biologics COVID-19 vaccine shows high antibody levels in Russian trials
Hungary's government signs deal with China's Sinopharm for COVID-19 vaccine purchase
Meijer collaborates with the State of Michigan for COVID-19 vaccine administration
African Union secures 270 million COVID-19 vaccine doses from WHO's COVAX initiative